Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price fell 6.9% during mid-day trading on Thursday . The stock traded as low as $6.62 and last traded at $6.64. 6,100,949 shares traded hands during trading, a decline of 0% from the average session volume of 6,122,622 shares. The stock had previously closed at $7.13.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RXRX. Jefferies Financial Group cut their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Finally, Leerink Partners cut their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Trading Down 3.6 %

The company has a fifty day simple moving average of $6.60 and a two-hundred day simple moving average of $7.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market capitalization of $1.97 billion, a P/E ratio of -4.34 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s revenue for the quarter was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $6.84, for a total value of $78,297.48. Following the sale, the director now directly owns 7,109,875 shares in the company, valued at $48,631,545. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 134,235 shares of company stock worth $895,538. Company insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Axxcess Wealth Management LLC boosted its holdings in Recursion Pharmaceuticals by 4.3% during the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after purchasing an additional 1,795 shares in the last quarter. Green Alpha Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 2.9% in the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after acquiring an additional 1,800 shares during the last quarter. Interchange Capital Partners LLC raised its stake in shares of Recursion Pharmaceuticals by 7.3% in the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after acquiring an additional 2,349 shares during the last quarter. Amalgamated Bank raised its stake in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in shares of Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after acquiring an additional 2,598 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.